- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05790122
Safety and Efficacy of Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1 Stage Renal Carcinoma
Partial nephrectomy(PN) and tumor enucleation(TE) are the two main methods of Nephron-sparing surgery for early renal cell carcinoma. Because of its blunt separation, TE is often considered to be difficult to completely remove tumor tissue. In addition, compared with PN, TE is more difficult and has higher professional requirements for surgeons. Therefore most surgeons use PN. But Many studies have shown that TE has advantages over PN such as less trauma, faster recovery, and better protection of renal function without increasing the risk of tumor recurrence.
The main renal artery should be clamped during PN to achieve a relatively bloodless operation environment to ensure the safety of tumor resection. However, too long warm ischemia time will inevitably affect the function of normal renal tissue. Studies have shown that shortening the time of renal ischemia is closely related to the recovery of renal function after the operation. So reducing the time of warm ischemia until zero ischemia has become the pursuit of surgeons. Based on renal cell carcinoma resection combined with zero ischemia technique, renal parenchyma, and renal function can be protected to the maximum extent on the premise of ensuring tumor safety.
The purpose of this study is to explore the safety and efficacy of zero-ischemia TE by analyzing the data of early renal cell carcinoma patients who had undergone PN and zero-ischemia TE before.
Study Overview
Status
Conditions
Detailed Description
According to the inclusion and exclusion criteria,collecting the data of participants who have undergone partial nephrectomy or renal tumor enucleation.
The investigators will compare the difference between TE and PN, clamped-enucleation and unclamped-enucleation, suture and sutureless zero-ischemia enucleation by the data the investigators collected.
After analysing the data, the investigators will discuss the safety and efficay of the sutureless zero-ischemia tumor enucleation. The patient who would be benefited from this operation and the patient who would be suggested to undergo this operation will also be discussed.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Yichun Zheng, Doctor
- Phone Number: 0571-87783550
- Email: springworld@yeah.net
Study Locations
-
-
Zhejiang
-
Yiwu, Zhejiang, China, 322000
- Recruiting
- The Fourth Affiliated Hospital Zhejiang University School of Medicine
-
Contact:
- Yichun Zheng, Doctor
- Phone Number: 057187783550
- Email: springworld@yeah.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 1. The age is between 18 and 80 years old.
- 2. Patients with T1a or T1b renal cell carcinoma according to TNM staging of AJCC renal cell carcinoma, 8th edition, 2017.
- 3. Patients who underwent unclamped renal tumor enucleation or partial nephrectomy between 2014 and 2022.
Exclusion Criteria:
- 1. The patients accompanied by severe active infection or severe diseases of heart, liver, kidney and hematopoietic system. And with other conditions that are not suitable for related tests.
- 2. The patient has no measurable or evaluable lesions.
- 3. The tumor is close to the collection system and touches the renal artery or renal vein. And other anatomy of tumor is not suitable for tumor enucleation.
- 4. History of organ transplantation or need long-term adrenocortical hormone therapy. Hypothyroidism, adrenal or pituitary dysfunction that cannot be controlled by hormone replacement therapy alone. type I diabetes mellitus, psoriasis or vitiligo that require systematic treatment, etc.
- 5. Active infection requiring systemic treatment. Human immunodeficiency virus (HIV) infection (known HIV antibody positive). Active HBV or HCV infection (HBsAg positive, or HBcAb positive but HBsAg negative, additional testing is required Quantitative DNA, the result does not exceed the upper limit of the laboratory normal value of the research center can participate in this study; the HCV RNA test result of the previous HCV infection screening period is negative, can participate in this study)
- 6. Patients have history of kidney surgery or any history of kidney inflammation surgery. Patients have kidney cancer related to urinary collection system and have other kidney diseases (including kidney stone glomerulonephritis)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Group PN
The patients undergoing partial nephrectomy.
|
Group TE
The patients undergoing renal tumor enucleation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operation time
Time Frame: Period of surgery
|
Operation time
|
Period of surgery
|
Estimated blood loss
Time Frame: Period of surgery
|
The estimated blood loss of operation
|
Period of surgery
|
Positive rate of incision margin
Time Frame: Period of surgery
|
Positive rate of incision margin
|
Period of surgery
|
Serum creatinine
Time Frame: Pre-operative, 1 day after the surgery and monthly follow-up in one year
|
Serum creatinine of patients before and after operation and follow-up
|
Pre-operative, 1 day after the surgery and monthly follow-up in one year
|
Collaborators and Investigators
Investigators
- Study Chair: Yichun Zheng, Doctor, The Fourth Affiliated Hospital Zhejiang University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K2023003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Neoplasms
-
St. Petersburg State Pavlov Medical UniversitySaint Petersburg State University, RussiaCompleted
-
Philips HealthcareWithdrawnKidney TumorsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedKidney TumorUnited States
-
Tianjin Medical University Second HospitalRecruiting
-
Thomas MuellerUnknownKidney Neoplasms | Adult Polycystic Kidney Disease | Kidney DysfunctionSwitzerland
-
Tianjin Medical University Second HospitalRecruiting
-
Intuitive SurgicalCompleted
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Not yet recruiting